16 results about "Thrombomodulin" patented technology

The present invention provides a method for detecting the presence of or risk of bladder cancer in a female patient, the method comprising the steps of: detecting the presence of a biomarker panel in a sample isolated from a female patient, the biomarker panel comprising IL-13 and IL-12p70 and one or more biomarkers selected from the group consisting of BTA, midkine, PAI-1 / tPA, 8OHdG, CEA, CK18, Fibrillin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9 NGAL, MMP9 TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglyceride, and / or the concentration of albumin / microalbumin / protein to creatinine in a sample isolated from a female patient, expressed as an albumin:creatinine ratio; and assessing the result and comparing it to a normal control, wherein an increase in the presence of the biomarkers compared to the normal control indicates the presence or risk of cancer in the patient from which the sample was isolated.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The present invention provides methods for modifying a donor organ, e.g., liver, or a portion thereof. The methods comprise contacting the donor liver with lipid nanoparticles comprising RNA. Compositions of lipid nanoparticles comprising RNA are also provided. The disclosed LNPs may comprise an siRNA, e.g., targeting tissue plasminogen activator (tPA) or plasminogen activator inhibitor 1 (PAI-1). The LNPs may comprise an mRNA encoding a protein, e.g., Nuclear Factor-erythroid factor 2-related factor 2 (NRF2) or thrombomodulin.

The invention is applicable to the technical field of immunodetection analysis, and provides a thromboregulatory protein quantitative detection kit and a preparation method thereof.The kit comprises a magnetic bead working solution, a biotin marker working solution, an acridinium ester marker working solution, a thromboregulatory protein calibration product and a thromboregulatory protein control product; the magnetic bead working solution is composed of streptavidin magnetic beads and a magnetic bead diluent, the biotin marker working solution is composed of a biotin-labeled thromboregulatory protein antibody and a biotin diluent, and the acridinium ester marker working solution is composed of an acridinium ester-labeled thromboregulatory protein antibody and an acridinium ester diluent. The thromboregulatory protein quantitative detection kit provided by the invention integrates high sensitivity, high specificity, high precision, strong anti-interference capability, wide linear range and excellent stability, and provides an ideal solution for realizing accurate, rapid and automatic quantitative detection of thromboregulatory protein.

The invention discloses an anti-thromboregulatory protein antibody and application thereof, and relates to the field of antibodies. The anti-thromboregulatory protein antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of thromboregulatory protein, and has good affinity or activity.

Methods for preventing or treating hair loss or promoting hair growth or regrowth are provided. More specifically, the present invention relates to compositions for preventing or treating hair loss and / or promoting hair growth on the scalp and / or skin of a subject in need thereof. The compositions comprise an effective amount of a polypeptide or a nucleic acid molecule encoding the polypeptide, wherein the polypeptide comprises an amino acid sequence having an EGF-like domain of thrombomodulin or a conservative variant thereof.

The invention discloses a fluorescence immunosensor for detecting thromboregulatory protein as well as a preparation method and a use method of the fluorescence immunosensor. The preparation method comprises the following steps: S5, adding a prepared buffer solution dissolved in Tris-HCl and a PNPP solution, and incubating; s6, dispersing nanoflowers stacked by fluorescent two-dimensional metal organic framework material Eu-MOF nanosheets into a Tris-HCl buffer solution, and carrying out ultrasonic treatment and oscillation to prepare an Eu-MOF nanosheet solution; and S7, adding the Eu-MOF nanosheet solution to ensure the total volume for testing, directly starting detection without any treatment, detecting the fluorescence intensity in the presence of different concentrations of thromboregulatory proteins by using a luminoscope, and constructing a fluorescence intensity-concentration working curve. According to the invention, the synthesized two-dimensional metal organic framework material Eu-MOF nanosheet has the characteristic of red fluorescence, so that the concentration of thromboregulatory protein in a sample is quantitatively analyzed.

The present application relates to the technical field of in vitro detection, in particular to a thrombomodulin chemiluminescence detection kit. The present application specifically provides a preparation method of carboxyl magnetic beads and application thereof, and the carboxyl magnetic beads prepared by the method have high carboxyl content on the surface and high coupling rate with antigens or antibodies. The thrombomodulin chemiluminescence detection kit prepared by the carboxyl magnetic beads provided by the present application has stable properties, good accuracy and repeatability of measurement, and can be applied to clinical use.

Provided are a novel pharmaceutical composition and a method for producing the pharmaceutical composition. Mesenchymal stem cells that overexpress thrombomodulin on the cell surface are used as an active ingredient of the pharmaceutical composition.

A method of treating or preventing alopecia or promoting hair growth or regeneration is provided. In particular to a composition for preventing or treating alopecia and / or promoting hair growth of the scalp and / or skin of a subject in need thereof. The composition comprises an effective amount of a polypeptide or a nucleic acid molecule encoding the polypeptide, and the polypeptide comprises an amino acid sequence having an EGF-like domain of clotting regulatory or a conservative variant thereof.

The invention relates to the technical field of protein detection kits, and discloses a thrombus regulatory protein detection kit and a preparation method and application thereof, the thrombus regulatory protein detection kit comprises a reagent M, a reagent R1, a reagent R2, a calibration product and a quality control product; the M reagent comprises a buffer solution I and a TM antibody-1 labeled by biotin coated with magnetic microspheres, and the magnetic microspheres are streptavidin magnetic particles; the R1 reagent comprises a buffer solution I; the reagent R2 comprises a buffer solution II and a TM antibody-2 marked by acridinium ester; both the calibration product and the quality control product are buffer solution dispersion liquid of thromboregulatory protein antigens. According to the scheme, a streptavidin magnetic particle-acridinium ester chemiluminescence system is used in a combined manner, so that the acridinium ester labeling operation is simple, the background luminescence is low, the signal-to-noise ratio is high, the luminous efficiency is high, the speed is high, and the advantages of better stability and repeatability, good linear relation, excellent sample coincidence rate and the like are shown.

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

This disclosure provides methods and devices for determining a quantitative estimate of thrombomodulin levels in a mammalian subject suspected of internal hemorrhaging. The method includes applying a blood sample from the subject to a handheld assay device capable of providing optical quantitation of the amount of thrombomodulin in the sample, measuring, by means of said assay device, an analyte signal value correlated to a concentration of the thrombomodulin in the blood sample and comparing the analyte signal value to a minimum threshold, wherein an analyte signal value less than the minimum threshold indicates that the subject is not internally hemorrhaging, and an analyte signal value above the minimum threshold indicates the subject is internally hemorrhaging. The methods and devices are adapted to rapidly assess internal hemorrhaging and hemorrhagic shock in a patient outside of hospital settings.

A method for optimizing osteoarthritis (OA) treatment by promoting chondrocyte cell proliferation and migration using thrombomodulin (TM) or soluble TM. This method involves blocking interleukin 1β (IL-1β)-mediated signaling to prevent the loss of bone integrity and maintain knee joint function. Additionally, the administration of miR-up-TM enhances the expression of TM protein, thereby protecting against cartilage damage and potentially preventing cartilage-related diseases.

A nucleic acid molecule comprising: a first polycistronic cassette comprising: TFPI (EPI / LACI), EPCR (PROCR), and thrombomodulin (THBD); a second polycistronic cassette comprising: B2M HLA-E fusion pr